Table 3.
Comparison among three disease subsets of MG.
| Early onset MG (n = 13) | Late‐onset MG (n = 7) | Thymoma‐associated MG (n = 16) | p value | |
|---|---|---|---|---|
| Age (years) | 40.3 ± 15.0 | 72.9 ± 6.8 | 53.9 ± 11.4 | <0.01 |
| Duration of eculizumab treatment (months) | 39.2 ± 26.1 | 42.7 ± 27.1 | 27.8 ± 18.3 | 0.509 |
| Immunosuppressive therapy | ||||
| Oral prednisolone | 13 (100%) | 7 (100%) | 16 (100%) | 1.000 |
| Calcineurin inhibitors | 12 (92%) | 6 (86%) | 15 (94%) | 0.782 |
| Fast‐acting treatment during eculizumab treatment | ||||
| Plasmapheresis | 1 (8%) | 1 (14%) | 0 | 0.302 |
| Intravenous immunoglobulin | 4 (31%) | 1 (14%) | 2 (13%) | 0.550 |
| Intravenous high‐dose methylprednisolone | 5 (38%) | 1 (14%) | 1 (6%) | 0.084 |
| Reduction of dairy dose of prednisolone (mg) | 3.8 ± 4.2 | 1.7 ± 2.8 | 4.8 ± 5.5 | 0.407 |
| MG activity of daily living | ||||
| Baseline | 11.5 ± 5.7 | 8.7 ± 4.2 | 8.2 ± 3.8 | 0.251 |
| Reduction | 6.2 ± 5.0 | 1.6 ± 4.6 | 2.1 ± 3.1 | 0.042 |
| Responders | 12 (92%) | 4 (57%) | 10 (63%) | 0.115 |
| Minimal manifestations or better | 5 (38%) | 2 (29%) | 6 (38%) | 1.000 |
| Adverse events | 3 (23%) | 3 (43%) | 3 (19%) | 0.529 |
| Discontinuation of eculizumab | 6 (31%) | 2 (29%) | 7 (44%) | 1.000 |
| Switch to ravulizumab | 6 (46%) | 4 (57%) | 5 (31%) | 0.459 |
MG, myasthenia gravis.